The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...

Kennedy selected a new team of medical professionals and scientists who are highly qualified and dedicated to public health.

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

RFK Jr approved the CDC-recommended age for RSV vaccination being lowered from 60 to 50 for high-risk adults.

This update marks a change from the CDC’s previous recommendation, which only offered the RSV shot to people 60 and older who were at high risk. HealthDay News — Adults as young as 50 may now qualify ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

This marks a change from the CDC’s previous recommendation, which only offered the shot to people 60 and older who were at high risk. HealthDay News — Adults as young as 50 may now qualify for an RSV ...